Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2015-10-05 Share Issue/Capital Cha…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it is providing 'Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social' (Monthly information relating to the total number of voting rights and shares comprising the share capital), referencing Article 223-16 of the AMF General Regulation. This type of filing, which reports changes in the total number of shares and voting rights, is a specific regulatory disclosure. While it relates to capital structure, it is not a general financing announcement (CAP) or a major shareholding notification (MRQ) which usually reports ownership thresholds crossed by external parties. It is a mandatory periodic disclosure about the company's own share count. Among the provided codes, this specific type of mandatory disclosure about the total number of shares/voting rights is best categorized as a general regulatory filing or a specific capital structure update. Given the options, 'Share Issue/Capital Change' (SHA) covers changes in capital structure, but this is a routine monthly disclosure of the *current* total, not an announcement of a new issue or buyback event. Since it is a mandatory regulatory report detailing share capital counts, and it doesn't fit perfectly into the more specific categories like DIV, DIRS, or MRQ, it falls closest to a general regulatory filing or a specific capital disclosure. However, the closest fit that deals with the composition of the capital is often grouped with share changes. Let's re-evaluate the definitions. This is a mandatory disclosure of the total share count, often required monthly. This is not a 'Transaction in Own Shares' (POS) unless it details a specific buyback, nor is it a 'Share Issue' (SHA) unless new shares were issued. Since it is a routine regulatory update on the capital base, and it is not a general earnings report or proxy, it fits best under the general 'Regulatory Filings' (RNS) as a fallback for specific, non-core disclosures, or potentially 'SHA' if interpreted broadly as capital structure reporting. Given the precise nature of the data (total shares/votes as of a specific date), and the reference to AMF regulations, it is a formal regulatory filing. RNS is the best fit for mandatory, non-financial/non-governance specific regulatory updates.
2015-10-05 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. This type of filing is a mandatory periodic disclosure in France concerning the total share capital and voting rights, typically issued monthly. This specific content—reporting the total number of shares and voting rights as of a specific date (August 31, 2015)—does not fit the definitions for Annual Reports (10-K), Interim Reports (IR), Earnings Releases (ER), or Dividend Notices (DIV). It is a specific regulatory disclosure related to capital structure changes or updates. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it relates directly to the capital structure, although 'RNS' (Regulatory Filings) is a general fallback. Given the specific nature of reporting total voting rights, which is a key component of capital structure reporting, SHA is the most appropriate specific classification over the general RNS, as it directly addresses changes/updates to the share base.
2015-09-04 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release dated July 28, 2015, announcing that Nanobiotix is eligible for the PEA-PME tax scheme for the second consecutive year. This announcement relates to the company's status regarding investment vehicles and compliance with specific French regulatory criteria (employee count, revenue, balance sheet total). This type of announcement, which details a specific corporate/financial status update that is not a standard periodic report (10-K, IR), dividend, or management change, fits best under a general regulatory or corporate update category. Since it is not a standard financing activity (CAP), director dealing (DIRS), or major shareholding change (MRQ), and it is a specific regulatory/tax status update, it is classified as a general Regulatory Filing (RNS) as it is a miscellaneous regulatory announcement.
2015-07-28 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 98% confidence The document is a press release dated July 15, 2015, announcing the company's revenue for the second quarter of 2015 (Q2 2015). It provides key financial figures (Revenues) in a table format and discusses recent clinical activity. This structure—a brief announcement of period-specific financial results, often including key highlights but not the full detailed report—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim Report (IR), as it focuses only on the revenue highlights and operational updates for the quarter, concluding with a note about the next financial release date. Q2 2015
2015-07-15 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document is titled "Chiffre d'affaires du deuxième trimestre 2015" (Revenue for the second quarter of 2015) and provides key financial figures (Compte de résultat) for Q2 2015 and the first half (S1) of 2015. It also includes updates on clinical activities and explicitly states the next financial communication date ("résultats semestriels 2015"). This structure—a brief announcement focusing on key financial highlights for a specific reporting period (quarterly/half-yearly) without the full depth of an Annual Report (10-K) or a comprehensive Interim Report (IR)—is characteristic of an Earnings Release (ER). Although it contains some operational details, its primary function is the immediate release of period-end financial performance metrics. The length (6741 chars) is substantial enough to be more than just a simple announcement (RPA), but it lacks the comprehensive structure of a full Interim Report (IR). Therefore, ER is the most appropriate classification. Q2 2015
2015-07-15 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is a short press release dated July 2, 2015, titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT" (Semi-annual statement of the liquidity contract with the stock brokerage firm Gilbert Dupont). It reports the status of the liquidity account (shares and cash balance) as of June 30, 2015, and compares it to the year-end 2014 balance. This type of regular update concerning share trading/liquidity management, especially when presented as a brief announcement, often falls under specific regulatory reporting or general corporate announcements. Since it details the status of shares held under a liquidity contract, it is closely related to share transactions or capital management. Given the options, it is not a full financial report (10-K, IR), an earnings release (ER), or a formal dividend notice (DIV). It is a specific update on the company's share position management. While it touches upon share activity, it is not a standard Director's Dealing (DIRS) or a general share issue (SHA/POS). It is a specific regulatory/contractual update. Because it is a short announcement detailing the status of a liquidity contract (which involves managing the company's own shares/cash for market stability), and it doesn't fit perfectly into the major financial reports, it is best classified as a general Regulatory Filing (RNS) or potentially related to Capital/Financing Update (CAP) if the liquidity contract is viewed as a financing tool. However, given its nature as a periodic disclosure about share holdings managed by a third party, RNS is the most appropriate fallback for specific, non-standard disclosures, or CAP if viewed strictly as capital management. Since it is a formal, periodic disclosure about the status of shares held under a specific agreement, and it is very short (2483 chars), it aligns well with the 'Regulatory Filings' (RNS) category as a miscellaneous regulatory disclosure, or potentially 'POS' (Transaction in Own Shares) if the liquidity provider is acting on behalf of the company to manage the float, but RNS is safer for periodic contractual updates. I will lean towards RNS as the most general fit for a specific, non-core financial disclosure.
2015-07-02 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.